Skip to main content
SpringerLink
Log in

Innovative Models for the Delivery Preventive Cardiovascular Care

  • Chapter
Preventive Cardiology

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 854 Accesses

Abstract

Our increasingly sophisticated understanding regarding the epidemiology, pathophysi-ology, and treatment of cardiovascular disease (CVD) has only served to underscore the continuing need for primary and secondary prevention efforts. Many of these insights have been incorporated into updated practice guidelines. At the same time, however, there is little evidence that the “treatment gap”—the troubling disparity between such endorsed guidelines and actual clinical practice–has narrowed. This is particularly true in ambulatory settings, and in clinical encounters in which a solo physician is the source of preventive services. The resulting need to translate research into practice for more effec-tive CVD prevention is undiminished, as is the opportunity to develop innovative models for such care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Heart Association. Heart Disease and Stroke Statistics. Dallas, TX, 2005.

    Google Scholar 

  2. Levy D. Atherosclerotic cardiovascular disease: An epidemiologic perspective. In: Topol EJ, ed. Textbook of Cardiovascular Medicine, 1998, Lippincott-Raven, Philadelphia, PA, p. 12–30.

    Google Scholar 

  3. National Center for Health Statistics: Vital Statistics of the United States. 1993, Washington, DC: US Government Printing Office, Public Health Service.

    Google Scholar 

  4. Mosca L, Ferris A, Fabunmi R, Robertson RM; American Heart Association. Tracking women’s awareness of heart disease: an American Heart Association national study. Circulation 2004; 109(5): 573–579.

    Google Scholar 

  5. Kannel WB, Vokonas PS. Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women. Ann Epidemiol 1992;2(1-2):5–14.

    PubMed  CAS  Google Scholar 

  6. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl): S1–9.

    PubMed  CAS  Google Scholar 

  7. Wolf P. Cerebrovascular risk. In: Izzo H, ed. Hypertension Primer: The Essentials of High Blood Pressure, 3rd ed. Lippincott Williams&Wilkins, Baltimore, MD, 2003, pp. 239–243.

    Google Scholar 

  8. American Heart Association. Statistical Update, American Heart Association. 1999.

    Google Scholar 

  9. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993;269(23):3002–3008.

    PubMed  CAS  Google Scholar 

  10. Thom TJ, Roccella EJ. Trends in blood pressure control and mortality. In: Izzo H, ed. Hypertension Primer: The Essentials of High Blood Pressure, 3rd ed. Lippincott Williams&Wilkins, Baltimore, MD, 2003, pp. 299–301.

    Google Scholar 

  11. Goldman L, Cook EF. The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 1984;101(6):825–836.

    PubMed  CAS  Google Scholar 

  12. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998;339(13):861–867.

    PubMed  CAS  Google Scholar 

  13. Kelly DT. Paul Dudley White International Lecture. Our future society. A global challenge. Circulation 1997;95(11):2459–2464.

    CAS  Google Scholar 

  14. Kannel WB. The Framingham Experience. In: Marmot M, Elliott P, eds. Coronary Heart Disease Epidemiology: From Aetiology to Public Health. 1992, Oxford University Press, New York, pp. 67–82.

    Google Scholar 

  15. Kannel WB. Cardiovascular risk factors and hypertension. In: Izzo H, ed. Hypertension Primer: The Essentials of High Blood Pressure, 3rd ed. Lippincott Williams&Wilkins, Baltimore, MD, 2003.

    Google Scholar 

  16. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998;158(18):2007–2014.

    PubMed  CAS  Google Scholar 

  17. Califf RM, Armstrong PW, Carver JR, D’Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996;27(5):1007–1019.

    PubMed  CAS  Google Scholar 

  18. Kannel WB, Wilson PW. An update on coronary risk factors. Med Clin North Am 1995;79(5):951–971.

    PubMed  CAS  Google Scholar 

  19. Ballantyne CM. Current thinking in lipid lowering. Am J Med 1998;104(6A):33S–41S.

    PubMed  CAS  Google Scholar 

  20. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109(3):433–438.

    PubMed  Google Scholar 

  21. Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation 2004;109(1):2–4.

    PubMed  Google Scholar 

  22. Hu G, Qiao Q, Tuomilehto, J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164(10):1066–1076.

    PubMed  Google Scholar 

  23. Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 2005;112(1):32–38.

    PubMed  CAS  Google Scholar 

  24. Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation 2003;108(13):1552–1553.

    PubMed  Google Scholar 

  25. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110(10): 1245–1250.

    PubMed  Google Scholar 

  26. Manson JE, Skerrett PJ, Greenland P, Van Itallie TB. The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med 2004;164(3):249–258.

    PubMed  Google Scholar 

  27. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288(21):2709–2716.

    PubMed  Google Scholar 

  28. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. 2000, National Cholesterol Education Program. National Institute of Health.

    Google Scholar 

  29. Canto JG, Iskandrian AE. Major risk factors for cardiovascular disease: debunking the “only 50%” myth. JAMA 2003;290(7):947–949.

    PubMed  Google Scholar 

  30. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the “only-50%” myth. Arch Intern Med 2001;161(22):2657–2660.

    PubMed  CAS  Google Scholar 

  31. Greenland P, Knoll MD, Stamler J, et al. Major risk factors asantecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290(7):891–897.

    PubMed  Google Scholar 

  32. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615–1622.

    PubMed  CAS  Google Scholar 

  33. Sacks FM, Pfeiffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001–1009.

    PubMed  CAS  Google Scholar 

  34. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20): 1301–1307.

    PubMed  CAS  Google Scholar 

  35. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339(19):1349–1357.

    Google Scholar 

  36. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383–1389.

    Google Scholar 

  37. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623–1630.

    PubMed  CAS  Google Scholar 

  38. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7–22.

    Google Scholar 

  39. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): amulticentre randomized controlled trial. Lancet 2003;361:1149–1158.

    PubMed  CAS  Google Scholar 

  40. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38.

    PubMed  CAS  Google Scholar 

  41. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–1504.

    PubMed  CAS  Google Scholar 

  42. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90(4):1679–1687.

    PubMed  CAS  Google Scholar 

  43. Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. Am J Cardiol 1994;73(15):1133–1134.

    PubMed  CAS  Google Scholar 

  44. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278(4):313–321.

    PubMed  CAS  Google Scholar 

  45. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227–239.

    PubMed  Google Scholar 

  46. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. Department of Health and Human Services, Rockville, MD, 1990.

    Google Scholar 

  47. The Health Consequences of Smoking: Cardiovascular Disease. A Report of the Surgeon General. Department of Health and Human Services: Rockville, MD, 1983.

    Google Scholar 

  48. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265(24):3255–3264.

    Google Scholar 

  49. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Shortterm reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827–838.

    PubMed  CAS  Google Scholar 

  50. Cutler J, Psaty B, MacMahon S, et al. Public health issues in hypertension. In: Laragh J, Brenner, B, ed. Hypertension: Pathologhysiology, Diagnosis and Management. Raven Press, New York, 1995.

    Google Scholar 

  51. Hebert PR, Fiebach NH, Eberlein KA, Taylor JO, Hennekens CH. The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol 1988;127(3):581–590.

    PubMed  CAS  Google Scholar 

  52. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993;153(5):578–581.

    PubMed  CAS  Google Scholar 

  53. Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol 1996;27(5):978–990.

    PubMed  CAS  Google Scholar 

  54. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96(8):2751–2753.

    PubMed  CAS  Google Scholar 

  55. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269(23):3015–3023.

    Google Scholar 

  56. de Lorgeril M, Salen P, Martin J-L, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99(6): 779–785.

    PubMed  Google Scholar 

  57. Esposito, K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292(12):1440–1446.

    PubMed  CAS  Google Scholar 

  58. Garber AJ. Vascular disease and lipids in diabetes. Med Clin North Am 1998;82(4):931–948.

    PubMed  CAS  Google Scholar 

  59. Aronson D, Rayfield, E. Diabetes. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Lippincott-Raven, Philadelphia, PA, 1998, pp. 171–194.

    Google Scholar 

  60. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339(4):229–234.

    PubMed  CAS  Google Scholar 

  61. Standards of Medical Care in Diabetes. Diabetes Care 2005;28(suppl 1):S4–S36.

    Google Scholar 

  62. Meigs JB, Singer DE, Sullivan LM, et al. Metabolic control and prevalent cardiovascular disease in noninsulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team. Am J Med 1997;102(1):38–47.

    PubMed  CAS  Google Scholar 

  63. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987;8:253–287.

    PubMed  CAS  Google Scholar 

  64. Blair SN, Kampert JB, Kohl HW III, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996;276(3):205–210.

    PubMed  CAS  Google Scholar 

  65. Blair SN, Kohl HW III, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995;273(14): 1093–1098.

    PubMed  CAS  Google Scholar 

  66. Erikssen G, Liestol K, Bjornholt J, Thaulow E, Sandvik L, Erikssen J. Changes in physical fitness and changes in mortality. Lancet 1998;352(9130):759–762.

    PubMed  CAS  Google Scholar 

  67. Wannamethee SG, Shaper AG, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 1998;351(9116):1603–1608.

    PubMed  CAS  Google Scholar 

  68. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA 1996;276(3): 241–246.

    Google Scholar 

  69. Niebauer J, Hambrecht R, Velich T, et al. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation 1997;96(8):2534–2541.

    PubMed  CAS  Google Scholar 

  70. Carnethon MR, Gidding SS, Nehgme R, Sidney S, Jacobs DR Jr, Liu K. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. JAMA 2003;290(23):3092–3100.

    PubMed  CAS  Google Scholar 

  71. Goto C, Higashi Y, Kimura M, et al. Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation 2003;108(5):530–535.

    PubMed  Google Scholar 

  72. Watkins LL, Sherwood A, Feinglos M, et al. Effects of exercise and weight loss on cardiac risk factors associated with syndrome X. Arch Intern Med 2003;163(16):1889–1895.

    PubMed  Google Scholar 

  73. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.

    PubMed  CAS  Google Scholar 

  74. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997;96(9):3248–3250.

    PubMed  CAS  Google Scholar 

  75. Schwartz MW, Brunzell JD. Regulation of body adiposity and the problem of obesity. Arterioscler Thromb Vasc Biol 1997;17(2):233–238.

    PubMed  CAS  Google Scholar 

  76. Kannel WB, D’Agostino RB, Cobb JL. Effect of weight on cardiovascular disease. Am J Clin Nutr 1996;63(3 Suppl):419S–422S.

    PubMed  CAS  Google Scholar 

  77. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997;337(6):396–407.

    PubMed  CAS  Google Scholar 

  78. Stone NJ. Diet, nutritional issues, and obesity. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Lippincott-Raven, Philadelphia, PA, 1998, pp. 31–58.

    Google Scholar 

  79. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282(22):2131–2135.

    PubMed  CAS  Google Scholar 

  80. Helmer DC, Ragland DR, Syme SL. Hostility and coronary artery disease. Am J Epidemiol 1991;133(2):112–122.

    PubMed  CAS  Google Scholar 

  81. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996;93(11):1976–1980.

    PubMed  CAS  Google Scholar 

  82. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993;270(15):1819–1825.

    PubMed  CAS  Google Scholar 

  83. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91(4):999–1005.

    PubMed  CAS  Google Scholar 

  84. Everson SA, Kaplan GA, Goldberg DE, Salonen R, Salonen JT. Hopelessness and 4-year progression of carotid atherosclerosis. The Kuopio Ischemic Heart Disease Risk Factor Study. Arterioscler Thromb Vasc Biol 1997;17(8):1490–1495.

    PubMed  CAS  Google Scholar 

  85. Kubzansky LD, Kawachi I, Spiro AIII, Weiss ST, Vokonas PS, Sparrow D. Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study. Circulation 1997;95(4):818–824.

    PubMed  CAS  Google Scholar 

  86. Olsen O. Impact of social network on cardiovascular mortality in middle aged Danish men. J Epidemiol Community Health 1993;47(3):176–180.

    PubMed  CAS  Google Scholar 

  87. Berkman LF, Leo-Summers L, Horwitz RI. Emotional support and survival after myocardial infarction. A prospective, population-based study of the elderly. Ann Intern Med 1992;117(12):1003–1009.

    PubMed  CAS  Google Scholar 

  88. Wassertheil-Smoller S, Shumaker S, Ockene J, et al. Depression and cardiovascular sequelae in postmenopausal women. The Women’s Health Initiative (WHI). Arch Intern Med 2004;164(3):289–298.

    PubMed  Google Scholar 

  89. Theorell T. The psycho-social environment, stress, and coronary heart disase. In: Marmot P, ed. Coronary Heart Disease Epidemiology: From Aetiology to Public Health, M.a.E. Oxford University Press, New York, 1992, pp. 256–273.

    Google Scholar 

  90. Empana JP, Sykes DH, Luc G, et al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2005;111(18):2299–2305.

    PubMed  CAS  Google Scholar 

  91. Smith T, Leon A. Coronary Heart Disease: A Behavioral Perspective. Smith T, Leon, A, ed. Research Press, Champaign, IL, 1992.

    Google Scholar 

  92. van Dixhoorn J, Duivenvoorden HJ, Staal JA, Pool J, Verhage F. Cardiac events after myocardial infarction: possible effect of relaxation therapy. Eur Heart J 1987;8(11):1210–1214.

    PubMed  Google Scholar 

  93. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92(3):657–671.

    PubMed  CAS  Google Scholar 

  94. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997;17(10):1859–1867.

    PubMed  CAS  Google Scholar 

  95. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332(8):512–521.

    PubMed  CAS  Google Scholar 

  96. Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90(2):1056–1069.

    PubMed  CAS  Google Scholar 

  97. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332(8):481–487.

    PubMed  CAS  Google Scholar 

  98. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332(8): 488–493.

    PubMed  CAS  Google Scholar 

  99. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87(6):1781–1791.

    PubMed  CAS  Google Scholar 

  100. Forrester JS, Shah PK. Lipid lowering versus revascularization: an idea whose time (for testing) has come. Circulation 1997;96(4):1360–1362.

    PubMed  CAS  Google Scholar 

  101. Pearson TA. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am J Cardiol 2004;94(9A):4F–8F.

    PubMed  Google Scholar 

  102. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ, 2005;331:614.

    PubMed  Google Scholar 

  103. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19:1434–1503.

    Google Scholar 

  104. 27th Bethesda Conference. Matching the Intensity of Risk Factor Management with the Hazard for Coronary Disease Events. September 14–15, 1995. J Am Coll Cardiol 1996;27(5):957–1047.

    Google Scholar 

  105. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:2560–2571.

    Google Scholar 

  106. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20(7):1183–1197.

    Google Scholar 

  107. Greenland P, Grundy S, Pasternak RC, Lenfant C. Problems on the pathway from risk assessment to risk reduction. Circulation 1998;97(18):1761–1762.

    PubMed  CAS  Google Scholar 

  108. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997;80(8B):45H–52H.

    PubMed  CAS  Google Scholar 

  109. Giles WH, Anda RF, Jones DH, Serdula MK, Merritt RK, DeStefano F. Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities. JAMA 1993;269(9):1133–1138.

    PubMed  CAS  Google Scholar 

  110. Miller M, Konkel K, Fitzpatrick D, Burgan R, Vogel RA. Divergent reporting of coronary risk factors before coronary artery bypass surgery. Am J Cardiol 1995;75(10):736–737.

    PubMed  CAS  Google Scholar 

  111. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. The Clinical Quality Improvement Network (CQIN) Investigators. Am J Cardiol 1995;76(8):570–573.

    Google Scholar 

  112. Frame PS, Kowulich BA, Llewellyn AM. Improving physician compliance with a health maintenance protocol. J Fam Pract 1984;19(3):341–344.

    PubMed  CAS  Google Scholar 

  113. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998;98(9):851–855.

    PubMed  CAS  Google Scholar 

  114. Cohen MV, Byrne MJ, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991;83(4):1294–1304.

    PubMed  CAS  Google Scholar 

  115. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM, Squair JL. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998;316(7142):1430–1434.

    PubMed  CAS  Google Scholar 

  116. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, betablockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med 1999;159(6):561–567.

    PubMed  CAS  Google Scholar 

  117. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S.et al. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA 1997;277(16): 1281–1286.

    PubMed  CAS  Google Scholar 

  118. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100(6):605–610.

    PubMed  CAS  Google Scholar 

  119. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of lowdensity lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82(1):61–65.

    PubMed  CAS  Google Scholar 

  120. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273(19): 1509–1514.

    PubMed  CAS  Google Scholar 

  121. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339(27):1957–1963.

    PubMed  CAS  Google Scholar 

  122. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005;294(4):466–472.

    PubMed  CAS  Google Scholar 

  123. Hill, MN, Levine DM, Whelton PK. Awareness, use, and impact of the 1984 Joint National Committee consensus report on high blood pressure. Am J Public Health, 1988. 78(9):1190–1194.

    PubMed  CAS  Google Scholar 

  124. Pearson TA, McBride PE, Miller NH, Smith SC. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service. J Am Coll Cardiol 1996;27(5):1039–1047.

    PubMed  CAS  Google Scholar 

  125. Pommerenke FA, Weed DL. Physician compliance: improving skills in preventive medicine practices. Am Fam Physician 1991;43(2):560–568.

    PubMed  CAS  Google Scholar 

  126. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah &WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989;321(19):1306–1311.

    PubMed  CAS  Google Scholar 

  127. Fix KN, Oberman A. Barriers to following National Cholesterol Educational Program guidelines. An appraisal of poor physician compliance. Arch Intern Med 1992;152(12):2385–2387.

    PubMed  CAS  Google Scholar 

  128. McBride PE, Pacala JT, Dean J, Plane MB. Primary care residents and the management of hypercholesterolemia. Am J Prev Med 1990;6(2):71–76.

    PubMed  CAS  Google Scholar 

  129. Heidenreich PA. Understanding and modifying physician behavior for prevention and management of cardiovascular disease. J Gen Intern Med 2003;18(12):1060–1061.

    PubMed  Google Scholar 

  130. Tierney WM, Overhage JM, Murray MD, et al. Effects of computerized guidelines for managing heart disease in primary care. J Gen Intern Med 2003;18(12):967–976.

    PubMed  Google Scholar 

  131. Ornstein S, Jenkins RG, Nietert PJ, et al. A multimethod quality improvement intervention to improve preventive cardiovascular care: a cluster randomized trial. Ann Intern Med 2004;141(7):523–532.

    PubMed  Google Scholar 

  132. Derose SF, Dudl JR, Benson VM, Contreras R, Nakahiro RK, Ziel FH. Point-of-Service reminders for prescribing cardiovascular medications. Am J Manag Care 2005;11(5):298–304.

    PubMed  Google Scholar 

  133. Schultz JS, O’Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005;11(5):306–312.

    PubMed  Google Scholar 

  134. Hill MN, Miller NH. Compliance enhancement. A call for multidisciplinary team approaches. Circulation 1996;93(1):4–6.

    PubMed  CAS  Google Scholar 

  135. Sikand G, Kashyap ML, Yang I. Medical nutrition therapy lowers serum cholesterol and saves medication costs in men with hypercholesterolemia. J Am Diet Assoc 1998;98(8):889–894; quiz 895–896.

    PubMed  CAS  Google Scholar 

  136. Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med 1995;155(21):2330–2335.

    PubMed  CAS  Google Scholar 

  137. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89(3):975–990.

    PubMed  CAS  Google Scholar 

  138. Harris DE, Record NB, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol 1998;81(7):929–933.

    PubMed  CAS  Google Scholar 

  139. Schectman G, Wolff N, Byrd JC, Hiatt JG, Hartz A. Physician extenders for cost-effective management of hypercholesterolemia. J Gen Intern Med 1996;11(5):277–286.

    PubMed  CAS  Google Scholar 

  140. Schultz JF, Sheps SG. Management of patients with hypertension: a hypertension clinic model. Mayo Clin Proc 1994;69(10):997–999.

    PubMed  CAS  Google Scholar 

  141. Reichgott MJ, Pearson S, Hill MN. The nurse practitioner’s role in complex patient management: hypertension. J Natl Med Assoc 1983;75(12):1197–1204.

    PubMed  CAS  Google Scholar 

  142. Weinberger M, Kirkman MS, Samsa GP, et al. A nurse-coordinated intervention for primary care patients with non-insulin-dependent diabetes mellitus: impact on glycemic control and health-related quality of life. J Gen Intern Med 1995;10(2):59–66.

    PubMed  CAS  Google Scholar 

  143. Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990;113(2):118–123.

    PubMed  CAS  Google Scholar 

  144. Taylor CB, Miller NH, Herman S, et al. A nurse-managed smoking cessation program for hospitalized smokers. Am J Public Health 1996;86(11):1557–1560.

    PubMed  CAS  Google Scholar 

  145. Miller NH, Smith PM, DeBusk RF, Sobel DS, Taylor CB. Smoking cessation in hospitalized patients. Results of a randomized trial. Arch Intern Med 1997;157(4):409–415.

    PubMed  CAS  Google Scholar 

  146. Lasater M. The effect of a nurse-managed CHF clinic on patient readmission and length of stay. Home Healthc Nurse 1996;14(5):351–356.

    PubMed  CAS  Google Scholar 

  147. Blair TP, Bryant FJ, Bocuzzi S. Treating hyperlipidemia. J Cardiovasc Nurs 1988;5:55–57.

    Google Scholar 

  148. Bruce SL, Grove SK. The effect of a coronary artery risk evaluation program on serum lipid values and cardiovascular risk levels. Appl Nurs Res 1994;7(2):67–74.

    PubMed  CAS  Google Scholar 

  149. Cofer LA. Aggressive cholesterol management: role of the lipid nurse specialist. Heart Lung 1997;26(5):337–344.

    PubMed  CAS  Google Scholar 

  150. DeBusk RF, Miller NH, Superko HR. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120(9):721–729.

    PubMed  CAS  Google Scholar 

  151. Gerber J. Implementing quality assurance programs in multigroup practices for treating hypercholesterolemia in patients with coronary artery disease. Am J Cardiol 1997;80(8B):57H–61H.

    PubMed  CAS  Google Scholar 

  152. Dunn PJ, Ryan MJ Jr, Hiebert M. Strategic and cost effective role for preventive cardiology. J Cardiovasc Manag 1998;9(6):13–20.

    PubMed  CAS  Google Scholar 

  153. Dunn PJ, Superko HR, Halbrook M, Wilson S, Hiebert M. Setting up a preventive cardiology program in the real world. J Cardiovasc Manag 1998;9(2):16–21.

    PubMed  CAS  Google Scholar 

  154. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149–1155.

    PubMed  Google Scholar 

  155. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;86:819–822

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Preventive Medicine, New Milford Hospital, New Milford, CT

    Joseph P. Frolkis MD, PhD, FACP

Authors
  1. Joseph P. Frolkis MD, PhD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

    Joanne Micale Foody MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Frolkis, J.P. (2006). Innovative Models for the Delivery Preventive Cardiovascular Care. In: Foody, J.M. (eds) Preventive Cardiology. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-096-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-096-6_17

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-521-7

  • Online ISBN: 978-1-59745-096-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation